United States

When the U.S. is the right choice

• Your case is complex and you want the broadest access to advanced lab capability and specialist depth.
• You want maximum optionality across pathways (including high-complexity male factor, advanced testing, and highly specialized protocols).
• You want strong infrastructure for international coordination and a high probability of finding a clinic model that fits your exact needs.
• Legal clarity is central to your plan (including state-level frameworks where relevant).
• You are willing to pay for premium execution when the outcome and risk profile justify it.

When it’s not

• Cost is your dominant decision variable and your case can be handled with equal quality in a lower-cost market.
• You want one predictable national framework — in the U.S., some rules and coverage are state-dependent.
• You want a purely “price-led” decision; the U.S. is a quality-and-capability decision.
• You prefer minimal planning. The U.S. works best with structured coordination and document readiness.

Clinic selection (how we think)

• We look for high-discipline operations: consistent protocols, strong lab staffing, and clean communication cadence.
• We prioritize clinics that can demonstrate fit for your pathway (not generic “highest success” marketing).
• We confirm what is included vs optional — and how the clinic handles international patients.
• We shortlist intentionally (typically 4–5), then structure the decision based on your constraints.

Legal and governance (strategic view)

• The U.S. can offer strong legal clarity in certain pathways, but rules can be state-dependent.
• We treat governance as a risk variable: jurisdiction choice, contracts (if relevant), and documentation readiness.
• The deliverable is not “legal advice” — it’s a structured risk map and a clear coordination plan.

Note: legal specifics depend on pathway and jurisdiction; we coordinate with vetted partners where needed.

Cost structure (strategic view)

• The U.S. is premium-priced. We only recommend it when capability, complexity, or risk reduction justify it.
• We map total cost as a system: base cycle + lab add-ons + meds/monitoring + storage + travel cadence.
• We avoid publishing numbers unless verified and updated; in advisory, we provide a decision-grade range.

Logistics and travel (including accommodation)

• The U.S. can be efficient if you structure remote consults and do on-site only when medically necessary.
• We include accommodation as part of execution: 2–3 vetted options near clinic access, chosen for comfort, predictability, and low friction.
• The goal is calm logistics during a high-stakes process — not “deal hunting.”